Introduction
============

Rheumatoid arthritis (RA), as the most common inflammatory disease, is associated with excess cardiovascular morbidity and mortality that is not entirely explained by traditional risk factors of cardiovascular disease (CVD) ([@b13-vhrm-4-1423]). It might be due to an increased prevalence of cardiovascular risk factors such as dyslipidemia ([@b51-vhrm-4-1423]). Risk factors for CVD, including inflammatory biomarkers, low intake of antioxidants, and vitamins, may contribute to excess CVD in persons with RA ([@b15-vhrm-4-1423]). There is a complex relationship between inflammation, antioxidant vitamin status, and the risk of CVD. Furthermore, low intakes of antioxidant vitamins and other micronutrients, including vitamin E, have been reported to be inversely associated with CVD incidence and mortality ([@b13-vhrm-4-1423]). Conjugated linoleic acids (CLAs) are a group of naturally occurring isomers of linoleic acid that differ in the position or geometry of their double bonds ([@b28-vhrm-4-1423]; [@b11-vhrm-4-1423]). The biological activities of CLAs have received considerable attention because of its anticancer ([@b54-vhrm-4-1423]), antiatherogenic ([@b62-vhrm-4-1423]; [@b3-vhrm-4-1423]) and antidiabetic effects ([@b55-vhrm-4-1423]). The atheroprotective properties of CLAs have been particularly well documented ([@b32-vhrm-4-1423]; [@b74-vhrm-4-1423]). Inclusion of CLAs in a hypercholesterolemic diet in rabbits led to a significant reduction in serum triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and cholesterol (CHO) levels. In addition, there was a reduced incidence of atherosclerotic plaque formation in the rabbit aorta ([@b34-vhrm-4-1423]). Similar results have also been reported for hamster hypercholesterolemia models ([@b47-vhrm-4-1423]; [@b81-vhrm-4-1423]). Despite these findings, some reports suggest that CLAs may possibly have proatherogenic effects ([@b44-vhrm-4-1423]; [@b17-vhrm-4-1423]). There are several molecular mechanisms for explaining the hypotriacylglycerolemic effect of CLAs. The cis-9, trans-11 and the trans-10, cis-12 isomers of CLAs are potent peroxisome proliferators-activated receptor (PPAR) agonists. PPARα is a key transcription factor that regulates hepatic lipid metabolism ([@b41-vhrm-4-1423]). Feeding CLAs-enriched diets increases the expression of PPARα-responsive genes in animals ([@b42-vhrm-4-1423]). Therefore, the TG-lowering effect of CLAs may be partly attributed to the effect of CLAs on PPARα. CLAs is also a PPARγ ligand. In adipose tissue, PPARγ regulates the expression of the genes that determine adipogenesis, lipid metabolism and insulin sensitivity ([@b37-vhrm-4-1423]; [@b41-vhrm-4-1423]). Some other proposed mechanisms include their role on peroxisome proliferators-sterol regulatory element-binding proteins (SREBPs) ([@b52-vhrm-4-1423]) and stearoyl-CoA desaturase (SCD) ([@b39-vhrm-4-1423], [@b40-vhrm-4-1423]; [@b50-vhrm-4-1423]). SREBP1c isoforms regulate fatty acid and TG synthesis ([@b52-vhrm-4-1423]). Studies suggest that liver SREBP-1c expression is dependent on the nuclear hormone liver X receptor (LXR). C9 t11 isomer was shown to down-regulate mRNA expression of LXR-α and SREBP-1c, whereas the t10 c12 isomer had no effect ([@b61-vhrm-4-1423]). The results suggested that c9t11 isomer positively influences lipid metabolism by reduced synthesis and cleavage of hepatic SREBP-1, which in turn is regulated by LXRα expression. SREBP-1c enhances the transcription of the genes required for fatty acid synthesis and fatty acid elongation including fatty acids synthetase (FAS) and SCD ([@b52-vhrm-4-1423]; [@b31-vhrm-4-1423]). Hypertension is also a common pathological state associated with an increased risk of cardiovascular diseases. Some studies have shown that CLAs (50:50) or the t10c12 isomer decreases blood pressure (BP) and hypertension in various rat models prone to develop obesity, diabetes and hypertension ([@b45-vhrm-4-1423], [@b46-vhrm-4-1423]; [@b2-vhrm-4-1423]). One possible mechanism is through inhibition of cyclooxygenases, both of them have been implicated in the development of atherosclerosis ([@b7-vhrm-4-1423]). c9, t11- and t10, c12-CLAs isomers are not substrates for cyclooxygenases (COX) but compete with arachidonic acid for access to the enzymes. In one study, it was seen that feeding rabbits with an atherogenic diet rich in CLAs reduced atherosclerotic lesion sizes ([@b79-vhrm-4-1423]). A number of studies in rabbits have considered the potential for the lipophilic antioxidant vitamin E to inhibit atherosclerosis in vitro by decreasing lipid peroxidation of LDL ([@b65-vhrm-4-1423]). Some epidemiological studies have shown an association between high dietary intake and high serum concentrations of vitamin E and lower rates of ischemic heart disease (Gey et al 1990; [@b58-vhrm-4-1423]; [@b70-vhrm-4-1423]) and myocardial infarction ([@b72-vhrm-4-1423]). Here, we investigated the effect of 50:50 blend of *c*9, *t*11: *t*10, *c*12-CLAs on BP and lipid profiles in active RA patients.

Materials and methods
=====================

Subjects
--------

A randomized double blind placebo controlled trial was conducted in a 12 week period in 87 patients with active RA. Patients were between 19--69 years old and had RA for at least 2 years fulfilling American College of Rheumatology (ACR) criteria of 1987 ([@b4-vhrm-4-1423]). The method for evaluation of disease activity was global physician assessment (GPA). Disease activity was determined by rheumatologist by medical history, pain in joints, morning stiffness, inflammation and tenderness and by acute phase reactants such as C-reactive protein (CRP), erythrocytes sedimentation rate (ESR), platelet (PLT), and hemoglobin (Hb). Data on dietary habits, dietary supplements, anthropometric indices including body mass index (BMI), smoking habits, and drug history were obtained by face to face interview. The exclusion criteria were: abnormal renal and/or hepatic function, smoking, and history of myocardial infarction, pregnancy, taking vitamins and/or mineral supplements, hyperlipidemia and taking drugs such as thyroid hormones, estrogens, progesterone, diuretics or β-blockers. A written informed consent was obtained from all participants. The research protocol was approved by the Ethics Committee of Tehran University of Medical Sciences. The patients were divided into four groups to receive randomly either CLAs (group C), vitamin E (group E), both CLAs and vitamin E (group CE) or placebo (group P). CLAs was prescribed 2 g daily as 2 capsules (each capsule was 1.25 g and contained 80% CLAs) containing both cis-9, trans-11 CLAs and trans-10, cis-12 triglyceride type CLAs in equal proportion and vitamin E (α-tocopherol, 400 mg). Corn oil was the placebo for vitamin E and high oleic sunflower (HOSF) was placebo for CLAs. These were assigned to one of the four treatment groups using random permuted blocks procedure. The amount of nutrients intakes were estimated using a 24-hour dietary recall questionnaire for two following days before and after the study and analyzing by Food Processor software (ESHA Research, Salem, OR).

The subjects were asked not to alter their usual diets and physical activity throughout the study and any changes in their medication were avoided whenever possible and if the patients did change their nonsteroidal anti-inflammatory drug (NSAIDs) intake they must write it in the special forms provided. Compliance with the supplementation was assessed by counting the number of capsules used and also by measuring changes in the serum vitamin E.

After 12--14 h overnight fasting, 10 ml blood samples were collected from each subject at the beginning and at the end of the three month trial.

Methods
-------

Blood samples were collected in trace element-free tubes. Aliquots of serum were transferred to polystyrene tubes which were immediately stored at −70 °C until analysis. Prostaglandin E2 (PGE2) was measured by ELISA-Monoclonal Kit (No 514010.1; Cayman Chemical Co, Ann Arbor, MI). Plasma CHO and TG concentrations were determined by an enzymatic assay adapted to microtiter plates using commercially available kits (Randox Labs, Crumlin, North Ireland). High-density lipoprotein cholesterol (HDL-C) was determined by Immunoinhibition Colorimetric method (EliTech, Seppim SAS Industrial, Sees, France). LDL-C was measured by enzymatic colorimetric method (EliTech, Seppim SAS Industrial). Fasting blood sugar (FBS) was measured by enzymatic colorimetric method (colorimetric). CRP values were determined with immunoturbidometric assay. In this method CRP gives a complex with polyclonal antibody and creates turbidity that has positive relation with CRP in sample. Arylestrase activity (AEA) was measured by phenylacetate that was used as a substrate to measure the AEA. Enzymatic activity was calculated from the molar absorptive coefficient of the produced phenol, one unit of AEA was defined as 1 mmol phenol generated per min under the above conditions and expressed as units/l of serum ([@b33-vhrm-4-1423]). Serum α-tocopherol was determined by high performance liquid chromatography ([@b64-vhrm-4-1423]). Hematological analyses were counted by an automated blood counter (Beckman Coulter, Miami, FL). ESR was measured using an ESR apparatus (Greiner Labor Technic GmbH, Germany). The systolic (SBP) and diastolic blood pressure (DBP) was measured after five minutes seated rest, the mean of two readings at baseline, and after three months of supplementation. Mean arterial pressure (MAP) was calculated using this formula (SBP + 2DBP)/3 ([@b12-vhrm-4-1423]).

Statistical analysis
--------------------

All values are expressed as mean ± standard error of mean. Log transformation was used to normalize the distribution of CRP. All other variables were normally distributed. Differences between four groups were compared by one-way analysis of variance (ANOVA) for continuous data and the *χ*2-test for categorical data. Post hoc comparisons were performed with Tukey test. Adjustment for differences in baselines covariates and changes in variables during study were performed by analysis of covariance. A value of P ≤ 0.05 was considered to be statistically significant. All data were analyzed using SPSS software (SPSS Inc., Chicago, IL).

Results
-------

As shown in [Table 1](#t1-vhrm-4-1423){ref-type="table"}, groups were similar with respect to the sex, age, duration of RA, BMI, and daily intake of vitamin E at the beginning of the study. There were no significant changes in BMI, physical activity, dietary intake or medication during the study period (data not shown).

[Table 2](#t2-vhrm-4-1423){ref-type="table"} shows the serum lipid, lipoprotein concentrations and BP before and after supplementation for subjects who completed the study. At baseline there were no significant differences between groups by ANOVA. Our study did not show any significant changes in plasma CHO or LDL-C concentrations in C and CE groups following three months of supplementation. Plasma levels of HDL-C increased nonsignificantly in the groups P, C, E, and CE by 0.9%, 1.23%, 2.35%, and 4.9%, respectively as compared with baseline. LDL-C increased in all groups, but this increase was significant in group E compared with baseline. We did not find any significant change in HDL-C and LDL-C concentrations among four groups. Total CHO, CHO/HDL-C and LDL-C/HDL-C ratios, and TG were not altered significantly after supplementation compared with baseline and between four groups. After three months of supplementation in the group C, SBP levels reduced significantly by 8% (117.36 ± 3.80 mmHg versus 108.04 ± 3.13 mmHg) (P \< 0.05) and DBP by 8.5% (72.36 ± 2.37 mmHg versus 66.14 ± 1.66 mmHg) (P \< 0.05). The MBP decreased as compared with baseline in groups C and CE, 8.3% and 5.66%, respectively ([Figure 1](#f1-vhrm-4-1423){ref-type="fig"}). The reduction of SBP in group C was significant compared with other groups (*P* \< 0.05) ([Figure 1](#f1-vhrm-4-1423){ref-type="fig"}).

[Table 3](#t3-vhrm-4-1423){ref-type="table"} shows the serum PGE2, FBS, CRP concentrations, AEA, ESR, WBC, PLT, and BMI before and after supplementation for subjects who completed the study. At baseline there were no significant differences between groups by ANOVA. PGE2 didn't alter significantly among groups and in each group as compared with baseline (*P* \> 0.05). ESR levels decreased significantly in groups C, E, and CE (P ≤ 0.05, P ≤ 0.05, P ≤ 0.001, respectively) in comparison with baseline and group CE had significantly lower ESR level than group P (P \< 0.05). CRP decreased nonsignificantly in all groups as compared with baseline, after three months of supplementation ([Figure 2](#f2-vhrm-4-1423){ref-type="fig"}), but this reduction was 55% in group E compared with baseline (P= 0.054). The reduction of WBC in group CE was significant compared with other groups (*P* \< 0.05) ([Table 3](#t3-vhrm-4-1423){ref-type="table"}). Platelet count decreased nonsignificantly in groups CE, C, and E. BMI and FBS changes weren't significance in all groups. AEA decreased nonsignificantly in Groups E, C, and P (*P* ≥ 0.05) and there weren't significant differences between 4 groups. Following the study Serum levels of α-tocopherol increased significantly in groups C, E and CE as compared with baseline (*P* ≤ 0.05, *P* ≤ 0.0001, *P* ≤ 0.0001, respectively) and in groups E and CE compared with group P (*P* ≤ 0.0001).

Discussion
==========

In RA disease, chronic systemic inflammation may contribute to the higher incidence of CVD. ([@b20-vhrm-4-1423]; Metosios et al 2007). To our knowledge; this is the first study which investigated the effects of CLAs and its combination with vitamin E in human with RA disease. In the present study, we didn't find any significant changes in the plasma levels of TG and CHO in any of the studied groups. The magnitude of the change in plasma TG concentrations in our study is comparable with that achieved following 50:50 CLAs supplementation in [@b8-vhrm-4-1423] study. They did not find any effect on plasma CHO, lipoprotein, or TG. [@b49-vhrm-4-1423] study did not show any modification of plasma CHO and lipoprotein concentrations in healthy subjects receiving the 50:50 CLAs mix, however they showed a decrease in the TG concentration. Some other studies showed that trans-10, cis-12 CLAs isomer may be the effective hypotriglycerolemic isomer ([@b17-vhrm-4-1423]; [@b36-vhrm-4-1423]). The TG-lowering effect of CLAs may be partly attributed to the effect of CLAs on PPARα. Furthermore, CLAs is a PPARγ ligand. In adipose tissue, PPARγ regulates the expression of the genes that determine adiposeness, lipid metabolism, and insulin sensitivity ([@b23-vhrm-4-1423]; [@b37-vhrm-4-1423]). In our study, there was a nonsignificant decrease in CHO in CE group. We used CLAs capsules with equal proportions of the cis-9, trans-11 and trans-10, cis-12 CLAs in triglyceride form. Recent vitro and animal studies suggest that the individual CLAs isomers may have different effects on lipid metabolism. Human studies regarding CHO-related parameters were not in line with the animal ones. The inconsistency of results may arise from the effects of particular CLAs consists the usual CLAs mix. Moreover, the dose of CLAs mix administered to humans, on a weight basis, was much lower than that for animal models and may not reach the effective level ([@b69-vhrm-4-1423]). However, the effects of the CLAs-enriched dairy products on blood lipids were more complex. In our study similar to [@b14-vhrm-4-1423] study after the consumption of the CLAs supplements, LDL-C, and HDL-C concentrations and the ratio of total to HDL-C and LDL-C to HDL-C were not significantly changed. [@b67-vhrm-4-1423] study results in patients with coronary heart disease were similar to our study and plasma TG concentration didn't change significantly in the vitamin E-supplemented group. A large base of epidemiological evidence suggests that a 1 mg/dl increment in HDL-C would be associated with a 2%--3% decrement in CVD risk ([@b19-vhrm-4-1423]). Our data show that supplementation of vitamin E and its combination with CLAs for at least three months can increase HDL-C nonsignificantly by 3.4% and 4.5%, respectively. Separate supplementation of CLAs did not improve serum HDL-C levels. The absence of such effects of CLAs supplementation should not be attributed to the interference of weight, physical activity, dietary intake or medication because these variables did not change during the study period and the patients had good compliance in taking their supplements. α-Tocopherol possibly has power to inhibit oxidation induced by α-tocopheroxyl radical ([@b66-vhrm-4-1423]) and known synergistic action between vitamin E and CLAs ([@b30-vhrm-4-1423]; [@b63-vhrm-4-1423]). Other studies have also shown that CLAs supplementation had no effect on HDL lipid composition ([@b47-vhrm-4-1423]; [@b17-vhrm-4-1423]; [@b71-vhrm-4-1423]). In our study, LDL-C increased in all groups and the difference between groups was not significant. [@b48-vhrm-4-1423] also showed that non-HDL-C concentrations were reduced by (9%--13%) in response to a CLAs-enriched diet. The LDL-C/HDL-C was reduced in the 80:20 CLAs group (27.2%) and the 50:50 CLAs group (22.4%), however these weren't significant ([@b48-vhrm-4-1423]). In our investigation, CLAs plus vitamin E was more effective than CLAs in reducing LDL-C/HDL-C, CHO/HDL-C, and CRP. In the present study, FBS didn't change significantly in four groups. Few studies have evaluated the effect of CLAs intake on glucose metabolism and insulin sensitivity in humans, but the available data suggest that glucose metabolism may be negatively affected by CLAs isomers. In [@b60-vhrm-4-1423] study, a significant increase in glucose levels was observed in both the CLAs and the control group. The increase was more pronounced in the control group ([@b60-vhrm-4-1423]). In another study, glucose levels increased significantly only in the group receiving the trans10 cis 12 isomer and not in the case of a mixture of different isomers. The increase was not significantly different from that which occurred in the control group ([@b59-vhrm-4-1423]). [@b69-vhrm-4-1423] also showed an increase (p = 0.054) in glycemia after the consumption of a mixture of CLAs isomers compared with the control group. They observed that insulin levels tended to increase after an intake of 2 g CLAs ([@b69-vhrm-4-1423]). Several other studies have shown no deleterious effects on glucose or insulin levels or sensitivity to insulin attributable to the consumption of different doses of CLAs enriched with cis 9, trans 11 or trans 10, cis 12 ([@b75-vhrm-4-1423]; [@b73-vhrm-4-1423]). Results on the effect of CLAs on glucose metabolism from animal studies are controversial ([@b23-vhrm-4-1423]; [@b71-vhrm-4-1423]; [@b77-vhrm-4-1423]). In our study, CLAs supplementation had no effect on body weight. This finding is in agreement with [@b82-vhrm-4-1423] who found no changes in body weight or body composition attributed to CLAs supplementation in human subjects. However some studies have reported that CLAs supplementation (4 g/d) had no effect on body weight, but they significantly reduced body fat ([@b69-vhrm-4-1423]). It was shown that, 9c, 11t-CLAs, 10t, 12c-CLAs inhibited arachidonic acid and collagen-induced platelet aggregation ([@b76-vhrm-4-1423]). In the present study, the number of platelet decreased nonsignificantly in groups P, C, and CE. [@b35-vhrm-4-1423] studied the effects of vitamin E (400 IU) on cholesterol levels of hypercholesterolemic patients receiving statins. Similar to our study they didn't find significant differences in any lipoprotein cholesterol fraction. However, unlike our study, a 6% decrease in HDL-C was detected within the vitamin E group (p \< 0.05) ([@b35-vhrm-4-1423]). Following our study, LDL-C increased in all groups, but this increase was only significant in group E. This increase may be due to increasing the size of LDL-C or changing its fractions or by increase of its half life by decreasing LDL-C oxidation. In our study AEA, decreased nonsignificantly in groups E, P, and C, but decreased as compared with baseline in group E (P = 0.068). We had nonsignificant differences between four groups. In one study on pedigreed baboons, dietary vitamin E improved LDL quality and showed two apparently paradoxical effects on HDL metabolism: lower HDL2 and higher apo A-I. These effects have contrasting associations with CVD risk and may help account for the mixed results from clinical trials of dietary vitamin E. In our study, nonsignificant reductions in serum AEA of lipoprotein-associated enzymes, Paraxonase1 (PON1) in all groups except group CE was shown. The presence of PON1 on HDL particles is considered to be a major source of protection from lipoprotein oxidation. Therefore, reduction of PON1 activity may be considered to be prooxidant and pro-atherogenic ([@b57-vhrm-4-1423]). Our results contradict results in rabbits and humans ([@b26-vhrm-4-1423]; [@b27-vhrm-4-1423]). This discrepancy may reflect differences in HDL size and composition properties among the species. Alternately, vitamin E-associated reduction in oxidative stress and oxidized LDL may have lowered the metabolic requirements for these enzymes to maintain the redox balance in the circulation. Then, through feedback mechanisms, the expression of PON1 may have been downregulated ([@b25-vhrm-4-1423]; [@b57-vhrm-4-1423]). Furthermore the differences between groups wasn't significant. Following of our study ESR levels decreased significantly in the groups C, E, and CE compared with baseline (*P* ≤ 0.05 *P* ≤ 0.05, *P* ≤ 0.001, respectively). ESR levels in group CE was significantly lower than group P (P ≤ 0.05). Vitamin E was reported to regulate transcription or activity of a number of genes involved in oxidative stress, proliferation, inflammation, and apoptosis ([@b16-vhrm-4-1423]; [@b78-vhrm-4-1423]; [@b1-vhrm-4-1423]). CRP dropped in all groups in comparison with baseline, but this decreased more in group E (P = 0.054). The reduction of WBC in group CE was significant compare with other groups (*P* \< 0.05) ([Table 3](#t3-vhrm-4-1423){ref-type="table"}). PLT count decreased nonsignificantly in CE, C, E groups. Consequently CLAs, vitamin E, and their combination are useful in reduction of inflammation. Many studies ([@b24-vhrm-4-1423]; [@b29-vhrm-4-1423]; [@b53-vhrm-4-1423]; [@b9-vhrm-4-1423], [@b10-vhrm-4-1423]; [@b63-vhrm-4-1423]) show the antioxidant effect of CLAs, but several studies performed on healthy and obese subjects have observed that CLAs administration is associated with an increase in some lipid oxidation and peripheral inflammation parameters ([@b59-vhrm-4-1423], [@b60-vhrm-4-1423]; [@b5-vhrm-4-1423], [@b6-vhrm-4-1423]; [@b68-vhrm-4-1423]). One of our aims was to investigate the effect of α-tocopherol and CLAs supplementation on BP. BP levels decreased significantly in the group C by 8% and 8.5% for DBP and MAP respectively, after three months of supplementation as compared with baseline. The reduction of SBP in group C was significant compared with the groups E and P ([Table 2](#t2-vhrm-4-1423){ref-type="table"}). [@b22-vhrm-4-1423] studied healthy primigravidas who had a family history of pre-eclampsia and diastolic notch. Calcium-CLAs supplementation reduced significantly the incidence of pregnancy-induced hypertension (PIH) in the study group (P = 0.01). Endothelial dysfunction was also significantly reduced after calcium-CLAs supplementation ([@b22-vhrm-4-1423]). [@b21-vhrm-4-1423] in another study on healthy primigravidas showed that the incidence of PIH was significantly reduced in women receiving the CLAs supplement compare with the placebo. There were no significant differences in the plasma concentrations of ionized calcium, PE2 (similar to our study), renin, angiotensin II, parathormone, and calcitonine ([@b21-vhrm-4-1423]). In [@b56-vhrm-4-1423] investigation, a diet rich in CLAs didn't alter SBP, DBP and pulse pressure, but this may be due to the short time for the study (five weeks). [@b45-vhrm-4-1423] found that the relative mRNA expressions of angiotensinogen and leptin were suppressed by 10t, 12c-CLAs in adipose tissue. They speculate that the antihypertensive effect of 10t, 12c-CLAs can be attributed to the lowered secretion of hypertensive adipocytokines from abdominal adipose tissues ([@b45-vhrm-4-1423]). In another study [@b46-vhrm-4-1423] showed that CLAs suppresses the development of nonobese essential hypertension in spontaneously hypertensive rats (SHRs). They concluded that the antihypertensive effect of dietary CLAs may be due to the increase of plasma adiponectin level and is associated with the alleviation of membrane abnormality in SHRs ([@b46-vhrm-4-1423]). In our study in group E, BP increased nonsignificantly, in [@b80-vhrm-4-1423] study BP, pulse pressure, and heart rate increased versus placebo.

Conclusion
==========

It is concluded that supplementation of 2 g CLAs 50:50 mix, and its combination with vitamin E for 12 weeks didn't change lipid profiles and FBS significantly, but CLAs decreased BP and vitamin E decreased CRP so co-supplementation of CLAs and vitamin E could be helpful for heart disease prevention in RA patients.

This study was funded through a research grant from the Research Deputy of Tehran University of Medical Sciences (with Proposal No., 2804). We appreciate the kind cooperation of both Lipid Nutrition Company (Nederland) for providing CLAs capsules as Clarinol G-80, and Zahravi Company (Iran) for providing vitamin E pearls for this research.
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![Levels of C-reactive protein (CRP) before and after three months vitamin E and conjugated linoleic acid (CLA) supplementation in patients with active rheumatoid arthritis.](vhrm-4-1423f2){#f2-vhrm-4-1423}

###### 

Demographic, anthropometric and biological data for the four groups before study (Mean ± SEM)

  Variables                       Placebo (n = 22)   Conjugated linoleic acids (CLAs) (n = 22)   Vitamin E (n = 21)   CLAs + vitamin E (n = 22)
  ------------------------------- ------------------ ------------------------------------------- -------------------- ---------------------------
  Male/Female                     3/19               3/19                                        4/17                 5/17
  Age (years)                     47.95 ± 2.37       46.23 ± 2.79                                49.33 ± 2.59         43.77 ± 12.75
  Duration of RA(years)           8.89 ± 2.06        9.95 ± 1.79                                 7.24 ± 1.27          7.64 ± 1.32
  BMI (kg/m^2^)                   28.48 ± 0.84       27.18 ± 0.99                                27.14 ± 1.03         25.65 ± 0.85
  Vitamin E intake (mg per day)   7.9 ± 0.53188      8.75 ± 0.51723                              7.78 ± 0.78260       8.80 ± 0.76936

**Note:** There were no significant differences between groups by ANOVA or Chi-square.

**Abbreviation:** BMI, body mass index.

###### 

Levels of lipid profile and blood pressure variables in patients with active rheumatoid arthritis before and after three months supplementation (Mean ± SEM)

  Variables                        Placebo (n = 22)                                           Conjugated linoleic acids (CLAs) (n = 22)   Vitamin E (n = 21)   CLAs + Vitamin E (n = 22)
  --------------- ---------------- ---------------------------------------------------------- ------------------------------------------- -------------------- --------------------------------------------------------
  TG (mg/dl)      before           120.45 ± 11.5                                              118.45 ± 9.83                               120.86 ± 9.34        125.91 ± 9.08
  after           124.91 ± 13.03   130.4 ± 18.32                                              132.47 ± 15.07                              126.18 ± 14.28       
  CHO (mg/dl)     before           191.32 ± 9.04                                              187.05 ± 7.94                               191.76 ± 10.68       197.68 ± 8.96
  after           198.27 ± 10.56   189.4 ± 9.04                                               201.76 ± 8.82                               193.86 ± 8.92        
  LDL-C (mg/dl)   before           104.14 ± 5.48[e](#tfn6-vhrm-4-1423){ref-type="table-fn"}   102.32 ± 4.43                               103.43 ± 5.51ª       106.36 ± 6.65
  after           114.86 ± 7.47    107.05 ± 5.00                                              114.85 ± 6.17                               113.50 ± 6.89        
  HDL-C (mg/dl)   before           49.50 ± 1.94                                               47.77 ± 2.36                                50.38 ± 2.79         47.18 ± 2.31
  after           49.95 ± 2.26     48.36 ± 2.06                                               51.57 ± 1.89                                49.50 ± 2.04         
  LDL/HDL         before           2.14 ± 0.12[f](#tfn7-vhrm-4-1423){ref-type="table-fn"}     2.19 ± 0.094                                2.12 ± 0.12          2.37 ± 0.19
  after           2.37 ± 0.17      2.33 ± 0.12                                                2.26 ± 0.12                                 2.32 ± 0.13          
  CHO/HDL         before           3.93 ± 0.19                                                3.99 ± 0.14                                 3.88 ± 0.19          4.36 ± 0.26[c](#tfn5-vhrm-4-1423){ref-type="table-fn"}
  after           4.08 ± 0.23      4.03 ± 0.20                                                3.89 ± 0.19                                 3.97 ± 0.17          

**Notes:** There were no significant baseline differences between groups by ANOVA. Statistically significant differences between before and after:

P ≤ 0.05. Statistically non significant differences between before and after:

P = 0.072. Statistically no significant differences between before and after:

P =0.086. Statistically no significant differences between before and after:

P = 0.065.

**Abbreviations:** CHO, cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL, low-density lipoprotein-cholesterol; TG, triglycerides.

###### 

Levels of blood pressure, oxidative stress variables in patients with active rheumatoid arthritis before and after three months supplementation (Mean ± SEM)

  Variables                                                                                Placebo (n = 22)   Conjugated linoleic acids (CLAs) (n = 22)                 Vitamin E (n = 21)                                         CLAs + Vitamin E (n = 22)
  ----------------------------------------------------------------------- ---------------- ------------------ --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Mean blood pressure (mmHg)                                              Before           90.54 ± 3.03       87.36 ± 2.64ª                                             86.81 ± 2.73                                               84.50 ± 2.48
  After                                                                   91.89 ± 3.06     80.10 ± 1.93       90.89 ± 3.52                                              79.71 ± 2.36                                               
  Min blood pressure (mmHg)                                               Before           74.72 ± 3.11       72.36 ± 2.37ª                                             71.81 ± 2.62                                               70.32 ± 2.39
  After                                                                   75.72 ± 2.78     66.14 ± 1.66       75.24 ± 2.95                                              65.27 ± 2.37                                               
  Max blood pressure (mmHg)[†](#tfn12-vhrm-4-1423){ref-type="table-fn"}   Before           122.18 ± 3.67      117.36 ± 3.80ª                                            116.8 ± 3.83                                               113.32 ± 3.25
  After                                                                   124.68 ± 4.19    108.04 ± 3.13      122.2 ± 5.52                                              108.59 ± 2.97                                              
  Aryl esterase activity (IU/ml)                                          Before           155.05 ± 10.68     159.45 ± 10.12                                            152.76 ± 8.47                                              146.77 ± 8.23
  After                                                                   147.64 ± 8.02    157.55 ± 11.58     140.14 ± 7.23                                             148.14 ± 11.51                                             
  PGE2                                                                    Before           607.91 ± 22.76     623.27 ± 21.87                                            593.81 ± 23.99                                             620.04 ± 20.34
  After                                                                   607.82 ± 18.08   613.45 ± 92.06     577.47 ± 18.49                                            605.04 ± 18.53                                             
  Serum vitamin E (μg/ml)                                                 Before           4.83 ± 0.81        4.72 ± 0.94[a](#tfn10-vhrm-4-1423){ref-type="table-fn"}   5.24 ± 0.63b[‡](#tfn13-vhrm-4-1423){ref-type="table-fn"}   6.64 ± 0.99b[ψ](#tfn14-vhrm-4-1423){ref-type="table-fn"}
  After                                                                   5.03 ± 0.79      5.51 ± 0.95        6.63 ± 0.92                                               7.78 ± 0.98                                                

**Notes:** There were no significant baseline differences between groups by ANOVA. Statistically significant differences between before and after:

P ≤ 0.05;

P ≤ 0.001, after supplementation;

Group C had significantly lower levels than group P and E (P ≤ 0.05);

E Group had significantly higher levels than P group (P ≤ 0.01).

CE Group had significantly higher levels than P group (P ≤ 0.05).

**Abbreviation:** PGE2.

###### 

Levels of FBS, inflammation variables and clinical tests in patients with active RA before and after three months supplementation (Mean ± SEM)

  Variables                                       Placebo (n = 22)   Conjugated linoleic acids (CLAs) (n = 22)                  Vitamin E (n = 21)                                         CLAs + vitamin E (n = 22)
  ---------------------------- ------------------ ------------------ ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------
  CRP (mg/l)                   Before             6.44 ± 1.68        7.18 ± 2.16                                                9.06 ± 3.12                                                5.23 ± 1.37
  After                        5.48 ± 1.19        5.46 ± 1.18        4.07 ± 0.99                                                3.17 ± 0.83                                                
  ESR (mm/h)                   Before             28.36 ± 4.59       26.81 ± 2.38[a](#tfn17-vhrm-4-1423){ref-type="table-fn"}   40.43 ± 5.72[a](#tfn17-vhrm-4-1423){ref-type="table-fn"}   28.45 ± 3.68‡[c](#tfn19-vhrm-4-1423){ref-type="table-fn"}
  After                        27.04 ± 4.04       19.14 ± 2.16       32.28 ± 5.01                                               17.77 ± 2.60                                               
  FBS (mg/dl)                  Before             90.18 ± 6.41       78.27 ± 1.95                                               90.85 ± 8.51                                               85.68 ± 6.15
  After                        85.04 ± 5.46       75.86 ± 1.41       78.05 ± 2.41                                               81.85 ± 3.14                                               
  WBC (/UL)                    Before             8587.72 ± 483.94   7728.57 ± 551.24                                           7724.76 ± 400.36                                           9280.95 ± 513.42[a](#tfn17-vhrm-4-1423){ref-type="table-fn"}
  After                        7752.95 ± 457.03   8533.33 ± 401.86   10276.2 ± 2373.9                                           8528.57 ± 491.99                                           
  Platelet count (\*1000/UL)   Before             269.07 ± 16.55     294.38 ± 12.49                                             300.57 ± 15.85                                             294.14 ± 16.95
  After                        278.13 ± 13.77     286.09 ± 13.98     279.86 ± 18.34                                             280.09 ± 14.96                                             
  BMI (kg/m^2^)                Before             27.92 ± 0.78       26.95 ± 0.94                                               27.14 ± 1.03                                               25.65 ± 0.85
  After                        28.66 ± 0.84       27.41 ± 4.49       27.97 ± 1.05                                               25.94 ± 0.76                                               

**Notes:** There were no significant baseline differences between groups by ANOVA. Statistically significant differences between before and after:

P ≤ 0.05;

P ≤ 0.01;

P ≤ 0.001;

P = 0.054.

**Abbreviations:** BMI, body mass index; CRP, C-reactive protein; ESR erythrocyte sedimentation rate; FBS, fasting blood sugar; WBC, white blood cells.
